Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of.  | The combined company is ...

Ligand Pharmaceuticals has struck a deal to combine its Pelthos Therapeutics unit with Channel Therapeutics in a bid to accelerate the commercialization of its Zelsuvmi treatment for molluscum ...

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching ...

Ligand Pharmaceuticals (LGND) and Channel Therapeutics (CHRO) announced the signing of a definitive merger agreement to combine Ligand’s wholly ...

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.

Proteins are fundamental biomolecules that perform a broad range of vital functions within the human body. They serve as an essential structural and functional component of cells, tissues and organs ...

Cysteinyl leukotrienes (CysLTs) are potent bronchoconstrictors, playing pivotal roles in inflammatory diseases. These lipid mediators exert their effects by activating two G protein-coupled receptors, ...

Understanding how molecules interact with ions is a cornerstone of chemistry, with applications from pollution detection and ...

Here, we explored how NMDARs signal in tLTD. We found that, regardless of frequency, L5 PC→PC tLTD relies on the non-ionotropic preNMDAR signaling pathway mediated by JNK2, which helps to resolve the ...

Mapping an antibody’s epitope, where it binds a target, can now be done in three dimensions, which optimizes the selection of application-specific antibodies.

These calculations are force-field-based and sample the whole complex (protein and ligand) in solvent. As an alternative, we used a DFT-based approach in which only a minimal model was considered for ...